Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

Vertex stock plummeted Thursday after the company's non-opioid pain drug proved it's no better than a placebo in patients ...

Although many dosing regimens for intravenous morphine have been studied, 0.10 mg/kg generally is recommended as an acceptable starting dose for treating patients with acute pain. Unfortunately ...

We developed a pain scale specific for rabbits to assess acute pain in a clinical environment. The BRPS allows the assessment of pain in both straight and lop-eared rabbits. The management of pain is ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

We then performed otoscopic examination and asked parents to complete 3 reference measures: A 10-point pain scale in which parents rated the severity of their child's pain from 0 ("no pain") to 10 ...

Pain was assessed using the UNESP-Botucatu Goat Acute Pain Scale (UGASP), with a score of 3 or higher classified as 'painful.' The goats included were of various breeds, ages, and sexes ...

Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.